Clinical Development Hormones Pharmacy 
XTalks
MARCH 17, 2025
Petrelintide, Zealand Pharmas long-acting amylin analog, is currently in Phase II clinical development and is designed for once-weekly subcutaneous injections. Amylin, a hormone co-secreted with insulin, plays a key role in regulating appetite by enhancing leptins effects the hormone that signals fullness after eating.
Pharmaceutical Technology
FEBRUARY 27, 2023
Enzalutamide is under clinical development by Pfizer and currently in Phase I for Relapsed Multiple Myeloma. EU, Asia and Japan and for non-metastatic high risk hormone sensitive prostate cancer. The drug candidate is also under development for castration-resistant prostate cancer in the Japan as a tablet formulation.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
FEBRUARY 27, 2023
Enzalutamide is under clinical development by Pfizer and currently in Phase I for Myelofibrosis. EU, Asia and Japan and for non-metastatic high risk hormone sensitive prostate cancer. The drug candidate is also under development for castration-resistant prostate cancer in the Japan as a tablet formulation.
Pharmaceutical Technology
FEBRUARY 27, 2023
Enzalutamide is under clinical development by Pfizer and currently in Phase I for Relapsed Chronic Lymphocytic Leukemia (CLL). EU, Asia and Japan and for non-metastatic high risk hormone sensitive prostate cancer. Pfizer sells its products through wholesalers, retailers, hospitals, clinics, government agencies and pharmacies.
XTalks
NOVEMBER 9, 2023
XTALKS WEBINAR: The Evolution of the Cardiovascular Clinical Development Landscape and Potential Role of GLP-1 RAs Live and On-Demand: Wednesday, December 6, 2023, at 11am EST (4pm GMT/UK) Register for this free webinar to learn about successful study outcomes in developing GLP1s to new therapeutic areas within cardiovascular medicine and more. “In
Expert insights. Personalized for you.
59 
Let's personalize your content